| Literature DB >> 36232358 |
Louise Winkel1, Morten Rasmussen1, Louise Larsen1, Louise T Dalgaard2, Jens H Nielsen1.
Abstract
In rats, the time of birth is characterized by a transient rise in beta cell replication, as well as beta cell neogenesis and the functional maturation of the endocrine pancreas. However, the knowledge of the gene expression during this period of beta cell expansion is incomplete. The aim was to characterize the perinatal rat pancreas transcriptome and to identify regulatory pathways differentially regulated at the whole organ level in the offspring of mothers fed a regular control diet (CO) and of mothers fed a low-protein diet (LP). We performed mRNA expression profiling via the microarray analysis of total rat pancreas samples at embryonic day (E) 20 and postnatal days (P) 0 and 2. In the CO group, pancreas metabolic pathways related to sterol and lipid metabolism were highly enriched, whereas the LP diet induced changes in transcripts involved in RNA transcription and gene regulation, as well as cell migration and apoptosis. Moreover, a number of individual transcripts were markedly upregulated at P0 in the CO pancreas: growth arrest specific 6 (Gas6), legumain (Lgmn), Ets variant gene 5 (Etv5), alpha-fetoprotein (Afp), dual-specificity phosphatase 6 (Dusp6), and angiopoietin-like 4 (Angptl4). The LP diet induced the downregulation of a large number of transcripts, including neurogenin 3 (Neurog3), Etv5, Gas6, Dusp6, signaling transducer and activator of transcription 3 (Stat3), growth hormone receptor (Ghr), prolactin receptor (Prlr), and Gas6 receptor (AXL receptor tyrosine kinase; Axl), whereas upregulated transcripts were related to inflammatory responses and cell motility. We identified differentially regulated genes and transcriptional networks in the perinatal pancreas. These data revealed marked adaptations of exocrine and endocrine in the pancreas to the low-protein diet, and the data can contribute to identifying novel regulators of beta cell mass expansion and functional maturation and may provide a valuable tool in the generation of fully functional beta cells from stem cells to be used in replacement therapy.Entities:
Keywords: ETS variant (Etv)5; Srebf2; alpha fetoprotein (Afp); angiopoietin-like (Angptl)4; anterior gradient (Agr)2; beta cell; beta cell maturation; dual-specificity phosphatase (Dusp)6; fetal metabolic programming; growth arrest specific (Gas6); hepatocyte nuclear factor (Hnf)-1α; legumain (Lgmn); lipid metabolism; neurogenin 3 (Neurog3); pancreas; perinatal gene expression; placenta-specific (Plac)8; sterol metabolic process; sterol response element binding factor (Srebf)-1
Mesh:
Substances:
Year: 2022 PMID: 36232358 PMCID: PMC9569808 DOI: 10.3390/ijms231911057
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1(A) Comparison of fold changes (FCs) in mRNA expression levels between P0 and E20 as obtained by hybridization to Affymetrix GeneChip versus RTqPCR for the number of selected up- and downregulated genes. There are no error bars, since data are presented as fold changes. Note: Pnlip: pancreatic lipase; Bcat2: branched-chain amino acid transaminase 2; Gas6: growth-arrest-specific 6; Afp: alpha-fetoprotein; Ngn3: neurog3; Srebf1/2: sterol regulatory element binding protein 1/2; Ins2: insulin 2; Pdx1: pancreatic duodenal homeobox 1; Egr1: early growth response factor 1. (B) Dendrogram for clustering using centered correlation and average linkage. Samples from P0 and P2 cluster closer together, indicating a more similar profile compared to samples from E20. (C) Heat map generated from the dCHIP hierarchical cluster analysis. Note: E20: embryonic day 20; P0: day 0 postpartum; P2: day two postpartum. Blue: Low expression. Red: High expression.
Fold changes (FCs) in most up- or downregulated annotated transcripts in control (CO) diet perinatal pancreas samples with corresponding changes listed for low-protein (LP) diet samples.
| Increased at P0 vs. E20 | Increased at P2 vs. P0 | ||||||
|---|---|---|---|---|---|---|---|
| Gene Symbol | Gene Name | FC CO | FC LP | Gene Symbol | Gene Name | FC CO | FC LP |
|
| Regenerating family member 3 alpha/beta | 461/335 | 617/617 |
| CD209 antigen | 5.1 | 1.8 |
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 | 270 | 55 |
| Protease, serine, 35 | 4.9 | 1.2 |
|
| Preprotrypsinogen IV | 155 | 103 |
| Complement C5 | 4.8 | −1.3 |
|
| Trypsin V-A | 145 | 151 |
| NGF-binding Ig light chain | 4.7 | 1.3 |
|
| Gastric intrinsic factor | 61 | 61 |
| Complement component 4a | 3.6 | 1.6 |
|
| Albumin | 58 | 12 |
| Adenylate kinase 5 isoform 1 | 3.4 | 1.6 |
|
| Angiopoietin-like 4 | 54 | 18 |
| Tubulointerstitial nephritis antigen | 3.1 | −1.5 |
|
| Apolipoprotein A1 | 39 | 117 |
| Serine protease inhibitor, Kazal type 3 | 2.9 | 1.7 |
|
| Pancreatic trypsin 1 | 30 | 15 |
| SUMO/sentrin specific protease 5 | 2.9 | 1.4 |
|
| Alpha-2-HS-glycoprotein | 29 | 19 |
| CUB and zona pellucida-like domains 1 | 2.9 | 1.1 |
|
| Serine protease inhibitor, Kazal type 1 | 29 | 11 |
| EGF-like-domain, multiple 6 | 2.9 | 2.0 |
|
| Kininogen 1 | 28 | 23 |
| Adenylate kinase 7 | 2.8 | −1.1 |
|
| Growth arrest specific 6 | 28 | 18 |
| Neurotrophin receptor associated death domain | 2.8 | 1.3 |
|
| Apolipoprotein B | 25 | 84 |
| Ret proto-oncogene | 2.7 | −1.0 |
|
| Solute carrier family 18 (vesicular monoamine), member 2 | 23 | 5.3 |
| Zinc finger, CCHC domain containing 12 | 2.6 | −1.1 |
|
|
| ||||||
|
|
|
|
|
|
|
|
|
|
| Serpin family A member 6 | −47 | −74 |
| Alpha-2-HS-glycoprotein | −31 | −1.4 |
|
| Hemoglobin subunit epsilon 1 | −44 | −30 |
| Fibrinogen, alpha polypeptide | −23 | −1.2 |
|
| Tubulointerstitial nephritis antigen | −30 | −7.6 |
| Fatty acid binding protein 1 | −23 | −1.3 |
|
| Troponin I, skeletal, slow | −28 | −23 |
| Kininogen 1 | −21 | −1.6 |
|
| Hemoglobin, gamma A | −27 | −19 |
| Apolipoprotein C-II | −19 | −4.6 |
|
| Histidine decarboxylase | −24 | −17 |
| Fibrinogen, gamma polypeptide | −17 | 2.0 |
|
| Prostaglandin E synthase | −22 | −14 |
| Apolipoprotein C-I | −16 | −1.2 |
|
| Transmembrane 7 superfamily member 2 | −17 | −4.1 |
| Apolipoprotein H | −15 | −1.0 |
|
| Phospholamban | −17 | −4.2 |
| Fibrinogen, beta polypeptide | −13 | −1.1 |
|
| N-acetylglutamate synthase | −17 | −3.2 |
| Apolipoprotein A-I | −13 | −5.4 |
|
| Chloride intracellular channel 3 | −13 | −7.1 |
| Hemopexin | −13 | −1.2 |
|
| A disintegrin and metalloprotease domain 2 | −12 | −9.8 |
| Serine protease inhibitor | −12 | −1.3 |
|
| Farnesyl diphosphate farnesyl transferase 1 | −12 | −4.4 |
| Inter-alpha trypsin inhibitor, heavy chain 3 | −10 | −1.2 |
|
| Chromodomain helicase DNA binding protein 9 | −11 | 1.2 |
| Phosphoenolpyruvate carboxykinase 1 | −9.9 | −5.3 |
|
| Calcium/calmodulin-dependent protein kinase kinase 2, beta | −11 | −2.4 |
| Serine peptidase inhibitor, clade A, member 3K | −9.7 | −1.2 |
Relative transcript abundances at the respective time points, sorted by differential expression in the CO diet. The top 15 up- or downregulated transcripts at each time point comparison are listed. Downregulation is denoted as a negative fold change. Only robustly expressed transcripts (intensity above 100 in at least one time point) were included.
Figure 2Expression and cellular localization of Afp in rat pancreas samples at E20, P0, and P2. (A,C,E) In situ hybridization of Afp mRNA using a dioxigenin-labeled LNA™ probe targeted against the same rat Afp sequence as the primers for RTqPCR (Qiagen, Exiqon, Vedbaek, Denmark) at E20 (A), P0 (C), and P2 (E). Afp is primarily expressed in association with islets of Langerhans in vessels and intra-islet capillaries. (B,D,F) Immunohistochemical detection (200× magnification) of Afp protein in 3 µm tissue sections from rat pancreas samples at E20 (B), P0 (D), and P2 (F). Afp is primarily detected in association with the endocrine compartments or ducts (arrows). Inserts at 400× magnification. (G) RTqPCR of Afp mRNA in rat pancreas samples at E20, P0, and P2. The mRNA values are normalized to Rpl13alpha. Afp mRNA expression is significantly increased at P0 compared to E20 and P2 (two-tailed t-test, p < 0.01). Note: *** p < 0.001.
Figure 3Functionally annotated gene clusters in normal perinatal rat pancreas samples. Differentially regulated transcripts in perinatal rat pancreas were clustered according to expression profiles over time and analyzed for enriched functional annotations using DAVID Functional Annotation Clustering. The most significantly enriched biological process in the highest scoring cluster is presented above each graph. Data points represent mean intensities of the associated gene cluster at the given time point. (A) Lipid metabolic process, (B) proteolysis, (C) activation of the immune system, (D) cell development, (E) sterol biosynthetic process, (F) alcohol metabolic process. Error bars (SE) are included to illustrate the variability in expression levels. p-value: modified one-tailed Fisher’s exact probability value (EASE score); E-score: enrichment score, the geometric mean (in -log scale) of a member’s p-values (EASE scores) in the corresponding annotation cluster.
Figure 4Relative Ins2, Pdx-1, Neurog3, Ghr, and Prlr mRNA expression in perinatal rat pancreas from control (Ctrl) and low-protein (LP) diet animals. Messenger RNA levels measured using RTqPCR in whole rat pancreas samples at days E20, P0, and P2. Values are normalized to levels at E20 within each data set, n = 3–6. Data are given as means + SEM. (A) Ins2, (B) Pdx1, (C) Neurog3, (D) Ghr, (E) Prlr, and (F) immunohistochemical stainings for Neurog3 in the perinatal rat pancreas at P0 (200× magnification). Data in panels (A–E) were tested using 2-way ANOVA with Bonferroni post tests for control vs. LP animals. Asterisks indicate significance levels of individual comparisons. Note: ** p < 0.01, *** p < 0.001.
Differential expression caused by the low-protein (LP) diet at E20, P0, and P2 in the 10 most up- or downregulated transcripts.
| Gene Symbol | Gene Name | E20 | Gene Symbol | Gene Name | P0 | Gene Symbol | Gene Name | P2 |
|---|---|---|---|---|---|---|---|---|
| Increased | LP vs. Control (Fold Regulation) | Increased | LP vs. Control (Fold Regulation) | Increased | LP vs. Control (Fold Regulation) | |||
|
| Angiotensin II receptor, type 2 | 11 |
| Apolipoprotein A4 | 142 |
| Lectin, galactose binding, soluble 4 | 236 |
|
| Muscleblind-like 1 isoform d | 8.7 |
| Pepsinogen 5 | 112 |
| Pepsinogen 5 | 215 |
|
| Caveolin | 8.6 |
| Retinol binding protein 2 | 86 |
| Anterior gradient 2 | 110 |
|
| Calcineurin B, type I | 8.5 |
| Lectin, galactose binding, soluble 4 | 79 |
| Resistin like alpha | 93 |
|
| Zinc finger protein 260 | 7.7 |
| Trefoil factor 1 | 73 |
| Fatty acid binding protein 1 | 92 |
|
| Septin 2 | 7.6 |
| Chloride channel calcium activated 3 | 55 |
| Trefoil factor 1 | 87 |
|
| Osteoglycin | 7.4 |
| Anterior gradient 2 | 48 |
| Gastrokine 1 | 82 |
|
| Methionine adenosyltransferase II, alpha | 6.3 |
| Fatty acid binding protein 2 | 46 |
| Prochymosin | 66 |
|
| Interleukin 13 receptor, alpha 1 | 5.9 |
| Chloride channel calcium activated 6 | 45 |
| Chloride channel calcium activated 3 | 42 |
|
| Solute carrier family 30 (zinc transporte), member 9 | 5.6 |
| Gastrokine 1 | 42 |
| Sulfotransferase family 1B | 39 |
|
|
|
|
|
|
|
|
|
|
|
| FBJ murine osteosarcoma viral oncogene | −14 |
| Myosin Vc | −5.1 |
| ATPase, Class I, type 8B, member 1 | −11 |
|
| Chromodomain helicase DNA binding protein 9 | −12 |
| Chromodomain helicase DNA binding protein 9 | −4.3 |
| AF4/FMR2 family, member 4 | −9.9 |
|
| Zinc finger homeobox 1b (ZEB2) | −6.8 |
| GTL2, imprinted maternally expressed untranslated | −4.2 |
| Forkhead box O1A | −9.6 |
|
| Ataxin 2 | −6.7 |
| SPARC-related modular calcium binding protein 1 | −4.1 |
| Eukaryotic translation initiation factor 2C, 2 | −9.4 |
|
| CBL E3 ubiquitin protein ligase | −6.4 |
| Ras-related protein Rab-1B | −4.1 |
| Tensin | −9.0 |
|
| Adiponectin receptor 2 | −6.1 |
| Laminin, gamma 1 | −3.9 |
| A kinase (PRKA) anchor protein 9 | −8.9 |
|
| Eukaryotic translation initiation factor 2C, 2 | −5.8 |
| Alcohol dehydrogenase, iron containing, 1 | −3.9 |
| Absent, small, or homeotic)-like | −8.8 |
|
| Metallothionein 1a | −5.8 |
| Fibroblast growth factor receptor 1 | −3.8 |
| DEAD box protein | −7.4 |
|
| Transducin (beta)-like 1 X-linked | −5.8 |
| P34 protein | −3.7 |
| Transducin (beta)-like 1 X-linked | −7.4 |
|
| ATPase, Class I, type 8B, member 1 | −5.4 |
| Cyclin L2 | −3.5 |
| Ubinuclein 1 | −6.7 |
Relative transcript abundances at the respective time points. Downregulation is denoted as a negative fold change. Only robustly expressed transcripts (intensity above 100 for at least one time point) were included.
Figure 5Gene Ontology biological processes and molecular functions,) which are significantly over-represented in the gene lists of differentially expressed genes at E20 vs. P0, and significantly enriched transcription factor binding sites (TFBS) based on differentially regulated genes between P0 and P2.
Figure 6Cluster analysis of genes regulated by gestational low-protein diet. (A,B) Venn diagrams based on lists of upregulated (A) and downregulated (B) genes in the perinatal pancreas (E20, P0, and P2) programmed by the low-protein diet during gestation. (C) Heat map and cluster analyses of low-protein diet-regulated genes in the perinatal period. LP: Low-protein; CO: control. Green: Upregulated and Red: Down regulated.
Figure 7Gene Ontology biological processes (GO:BP) and molecular functions (GO:MF), which are significantly over-represented in the gene lists of downregulated genes caused by the low-protein diet, and significantly enriched transcription factor binding sites (TFBS) based on downregulated genes caused by the low-protein diet during gestation.